Clinically relevant impairment of renal function was defined as SC≥1, GF<80 or GF<60 mL/ min/1.72m2. Results. Advanced fibrosis was predominant in our cohort (F3, 31%; F4, 55%), although less advanced stages were also present (F0-1, 5%; F2, 9%). Overall, SC and GF showed similar behavior when evaluating relationships with variables influencing renal function. Median renal function significantly decreased while receiving PI treatment click here and recovered after PI withdrawal (12% decrease, p<0.005), disregarding fibrosis stage. However, GF<80 mL/min/1.72m2 during treatment was associated with clinical decompensation

in cirrhotic patients (p=0.035). In survival analysis, BVR showed slightly longer time to clinically relevant renal impairment than TVR (39 vs 34 weeks, p=0.003). This implied a lower frequency for clinically relevant impairment of renal function which remained during treatment (31% small molecule library screening vs 40%, p=0.020). Although multivar-iate analysis demonstrated that clinically relevant impairment

of renal function was more associated with variables affecting pre-treatment status as gender (OR: 5.11; 95% CI: 3.21-8.16), age (OR: 2.47; 95% CI: 1.60-3.83), basal albumin level (OR: 1.76; 95% IC: 1.08-2.90) and cardiovascular disease (OR: 1.62; 95% IC: 1.03-2.57), there was still an independent association for PI treatment (OR: 0.601; 95% IC: 0.408-0.886). Conclusions. While first generation PIs predominantly have hepatic metabolism, we show for the first time that renal function impairment also happens

when treating immunocompetent patients which might lead even to clinical decompensation of cirrhosis. BVR showed a mildly lesser risk for clinically relevant impairment of renal function. Renal medchemexpress function should be monitored in patients with specific risk factors under PIs treatment. Disclosures: Xavier Forns – Consulting: Jansen, MSD, Abbvie; Grant/Research Support: Roche, MSD, Gilead Javier García-Samaniego – Consulting: Bristol-Myers-Squibb, Gilead, Roche Manuel Romero-Gomez – Advisory Committees or Review Panels: Roche Far-ma,SA., MSD, S.A., Janssen, S.A., Abbott, S.A.; Grant/Research Support: Ferrer, S.A. Juan Turnes – Advisory Committees or Review Panels: Roche, Janssen, BMS; Speaking and Teaching: Roche, MSD, Gilead, Janssen, BMS, Abbvie Maria Buti – Advisory Committees or Review Panels: Gilead, Janssen, Vertex, MSD; Grant/Research Support: Gilead, Janssen; Speaking and Teaching: Gil-ead, Janssen, Vertex, Novartis The following people have nothing to disclose: Carlos Fernández-Carrillo, Juan Manuel Pascasio, Martin Prieto, J. L. Montero, Javier Crespo, Inmaculada Fernán-dez, J. Javier Moreno, Elba Llop, Cristina Serrano-Millan, Jose Luis Calleja Background Within the UK the main source of hepatitis C virus (HCV) infection is injecting drug use.